Since Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) and CEL-SCI Corporation (NYSEAMERICAN:CVM) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation of both companies.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Paratek Pharmaceuticals Inc.	5.17M	44.87	111.46M	-3.64	0.00
CEL-SCI Corporation	N/A	161.07	24.42M	-1.72	0.00

Table 1 highlights Paratek Pharmaceuticals Inc. and CEL-SCI Corporation’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows the return on equity, net margins and return on assets of the two firms.

	Net Margins	Return on Equity	Return on Assets
Paratek Pharmaceuticals Inc.	-2,155.90%	-132.5%	-44.6%
CEL-SCI Corporation	0.00%	704.1%	-97.8%

Risk & Volatility

A beta of 1.03 shows that Paratek Pharmaceuticals Inc. is 3.00% more volatile than Standard and Poor’s 500. CEL-SCI Corporation’s 16.00% less volatile than Standard and Poor’s 500 which is a result of the 0.84 beta.

Liquidity

Paratek Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 11.4 and 11.4 respectively. The Current Ratio and Quick Ratio of its competitor CEL-SCI Corporation are 0.4 and 0.3 respectively. Paratek Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to CEL-SCI Corporation.

Analyst Ratings

In next table is given Paratek Pharmaceuticals Inc. and CEL-SCI Corporation’s ratings and recommendations.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Paratek Pharmaceuticals Inc.	0	1	1	2.50
CEL-SCI Corporation	0	0	0	0.00

$13.5 is Paratek Pharmaceuticals Inc.’s average price target while its potential upside is 87.76%.

Insider & Institutional Ownership

Institutional investors owned 82.6% of Paratek Pharmaceuticals Inc. shares and 6.6% of CEL-SCI Corporation shares. 2.9% are Paratek Pharmaceuticals Inc.’s share owned by insiders. Insiders Competitively, owned 5.6% of CEL-SCI Corporation shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Paratek Pharmaceuticals Inc.	-9.11%	-11.05%	-31.2%	-36.88%	-61.02%	-61.56%
CEL-SCI Corporation	-3.66%	-0.32%	-18.56%	13.67%	79.55%	67.21%

For the past year Paratek Pharmaceuticals Inc. had bearish trend while CEL-SCI Corporation had bullish trend.

Summary

On 6 of the 10 factors CEL-SCI Corporation beats Paratek Pharmaceuticals Inc.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The companyÂ’s Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.